Valion Bio delays third-quarter report to finalize financial statements
VBIO•Valion Bio delayed its Form 10-Q for the quarter ended September 30, 2026, and expects to file within the five-calendar-day extension. Preliminary net loss was about $16.2 million for the quarter and $29.5 million for the first nine months, compared with $2.6 million and $6 million a year earlier.
1. Filing delay and losses
Valion Bio delayed its Form 10-Q for the quarter ended September 30, 2026, saying it needs additional time to finalize its financial statements and disclosures. The company expects to file within the five-calendar-day extension. Preliminary net loss was approximately $16.2 million for the quarter, versus $2.6 million a year earlier, and approximately $29.5 million for the nine months, compared with $6 million in 2025. The wider losses primarily reflected asset and goodwill impairments, higher operating expenses and interest expense.




